Class Action Lawsuit Against PepGen Inc. Seeks Investor Restitution

Summary of Class Action Against PepGen Inc.

On June 30, 2025, The Gross Law Firm announced the filing of a class action lawsuit against PepGen Inc. (NASDAQ: PEPG), a biotech firm specializing in innovative therapies for diseases associated with the nervous system. This legal action is particularly pertinent to shareholders who acquired shares during a specific timeframe from March 7, 2024, to March 3, 2025. The suit addresses alleged misleading statements made by the company that may have inflated its stock value and impacted investor decisions.

Allegations in the Lawsuit

The allegations state that during the class period, PepGen's executives reportedly communicated that their lead product candidate, PGN-EDO51, was effective and safe. However, evidence suggests that the product's actual effectiveness and safety may have been overstated, leading to investor misinformation. Moreover, it has been alleged that the phase two trial known as the CONNECT2 study was fraught with dangers and deficiencies that could jeopardize its approval by the U.S. Food and Drug Administration (FDA).

The lawsuit also points to the stark possibility that PepGen would be compelled to halt the CONNECT2 study entirely due to these concerns, thus adversely affecting the company's clinical and commercial prospects. The claims emphasize that information which was materially important to the investors was not disclosed properly.

Importance of Registration for Shareholders

Shareholders who purchased PepGen shares within the specified period are encouraged to register for participation in this class action. It's important to note that individuals do not need to be designated as lead plaintiffs to receive potential recovery. The deadline for registering to be considered for lead plaintiff status is August 8, 2025. Registration is free of charge, making it accessible for affected shareholders to partake with no cost or obligation.

Once registered, participants will gain access to portfolio monitoring software designed to keep them updated on the ongoing case status, ensuring transparency and informed involvement in the proceedings.

The Role of The Gross Law Firm

The Gross Law Firm is known nationally for its expertise in class action lawsuits, dedicated to advocating for investors' rights. Their mission encompasses helping those harmed by corporate deceit and ensuring proper corporate accountability. The firm aims to recover losses incurred when investors are misled through intentional misinformation or concealment of vital information.

In summary, The Gross Law Firm’s initiative serves as a critical opportunity for those impacted by PepGen Inc.’s business practices to seek justice and restitution. The class action underscores the necessity for corporations to engage responsibly and transparently with their shareholders.

How to Get Involved

Investors wishing to join the lawsuit can click the following link to submit their claims: Submit Loss Information. As the legal process unfolds, it's imperative for affected shareholders to remain informed and engaged, securing their interests as the case progresses.

For more detailed inquiries, shareholders can contact The Gross Law Firm located at 15 West 38th Street 12th floor, New York, NY, 10018, by phone at (646) 453-8903 or by email at [email protected]